Omnicell, Inc. (NASDAQ: OMCL) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 38.37 | EPS (ttm) | 0.84 | Insider Own | 3.97% | Shs Outstand | 45.48M | Perf Week | -1.71% |
| Market Cap | 1.47B | Forward P/E | 15.42 | EPS next Y | 2.09 | Insider Trans | -1.17% | Shs Float | 43.91M | Perf Month | -11.53% |
| Enterprise Value | 1.35B | PEG | 9.29 | EPS next Q | 0.42 | Inst Own | - | Short Float | 7.50% | Perf Quarter | -17.46% |
| Income | 38.00M | P/S | 1.18 | EPS this Y | 170.09% | Inst Trans | - | Short Ratio | 4.35 | Perf Half Y | -3.50% |
| Sales | 1.25B | P/B | 1.13 | EPS next Y | -7.88% | ROA | 1.96% | Short Interest | 3.29M | Perf YTD | -28.85% |
| Book/sh | 28.41 | P/C | 4.77 | EPS next 5Y | 4.13% | ROE | 3.13% | 52W High | 55.00 -41.40% | Perf Year | 3.37% |
| Cash/sh | 6.75 | P/FCF | 10.55 | EPS past 3/5Y | -28.26% -43.06% | ROIC | 2.41% | 52W Low | 29.06 10.91% | Perf 3Y | -40.25% |
| Dividend Est. | - | EV/EBITDA | 12.83 | Sales past 3/5Y | -2.94% 5.85% | Gross Margin | 44.77% | Volatility | 2.65% 3.25% | Perf 5Y | -79.81% |
| Dividend TTM | - | EV/Sales | 1.08 | EPS Y/Y TTM | 211.11% | Oper. Margin | 4.73% | ATR (14) | 1.22 | Perf 10Y | -17.82% |
| Dividend Ex-Date | - | Quick Ratio | 1.43 | Sales Y/Y TTM | 12.14% | Profit Margin | 3.13% | RSI (14) | 35.86 | Recom | 2.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.64 | EPS Q/Q | 108.89% | SMA20 | -4.21% | Beta | 0.98 | Target Price | 56.67 |
| Payout | 0.00% | Debt/Eq | 0.16 | Sales Q/Q | 7.22% | SMA50 | -13.94% | Rel Volume | 1.28 | Prev Close | 32.62 |
| Employees | 3,485 | LT Debt/Eq | 0.16 | Earnings | Oct 29 | SMA200 | -20.57% | Avg Volume | 732.48K | Price | 32.23 |
| IPO Date | Aug 07, 2001 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 101.07% 0.64% | Net Debt/EBITDA | -0.87 | Volume | 937,122 | Change | -1.20% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | Wells Fargo | Overweight | $52 → $50 |
| Jul-31-26 | Reiterated | Keybanc | Overweight | $70 → $65 |
| Apr-29-26 | Reiterated | Craig-Hallum | Buy | $53 → $55 |
| Mar-13-26 | Reiterated | UBS | $53 → $60 | |
| Feb-06-26 | Reiterated | Piper Sandler | Overweight | $55 → $49 |
| Jan-16-26 | Reiterated | UBS | $53 | |
| Jan-08-26 | Upgrade | Keybanc | Sector Weight → Overweight | $60 |
| Jan-05-26 | Reiterated | Wells Fargo | Overweight | $35 → $52 |
| Aug-11-25 | Reiterated | Piper Sandler | Overweight | $61 → $55 |
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight | $40 → $35 |
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,247 | 1,185 | 1,112 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 689 | 677 | 641 | — | — | — | — | — | — | |
| Gross Profit | 558 | 508 | 471 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 410 | 409 | 380 | — | — | — | — | — | — | |
| Research and Development | 89 | 88 | 90 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 1 | — | — | — | — | — | — | |
| Operating Income | 58 | 12 | 0 | — | — | — | — | — | — | |
| Interest Expense | 4 | 4 | 5 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 4 | 30 | — | — | — | — | — | — | |
| Net Income Before Taxes | 62 | 11 | 26 | — | — | — | — | — | — | |
| Income Taxes | 23 | 9 | 13 | — | — | — | — | — | — | |
| Consolidated Net Income | 38 | 2 | 13 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 38 | 2 | 13 | — | — | — | — | — | — | |
| Net Income | 38 | 2 | 13 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.85 | 0.04 | 0.27 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.85 | 0.04 | 0.27 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.84 | 0.04 | 0.27 | — | — | — | — | — | — | |
| EBITDA | 105 | 102 | 120 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 38.37 | 1,022.57 | 164.89 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.16 | 1.76 | 1.84 | — | — | — | — | — | — | |
| Gross Margin | 44.75 | 42.87 | 42.36 | — | — | — | — | — | — | |
| Operating Margin | 4.65 | 1.01 | 0.00 | — | — | — | — | — | — | |
| Net Margin | 3.05 | 0.17 | 1.17 | — | — | — | — | — | — | |
| Shares Outstanding | 45 | 46 | 46 | — | — | — | — | — | — | |
| Market Capitalization | 1,450 | 2,084 | 2,048 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Njoku Nnamdi | President & COO | Aug 17 '26 | Sale | 36.85 | 3,083 | 113,609 | 161,224 | Aug 18 |
| LIPPS RANDALL A | CHAIRMAN, CEO | Jul 15 '26 | Sale | 47.00 | 10,000 | 470,000 | 345,861 | Jul 17 |
| Njoku Nnamdi | EVP, Chief Operating Officer | May 18 '26 | Sale | 43.22 | 3,090 | 133,550 | 154,785 | May 19 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | May 18 '26 | Sale | 43.22 | 5,025 | 217,181 | 112,783 | May 19 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Mar 16 '26 | Sale | 34.69 | 7,405 | 256,879 | 96,717 | Mar 17 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Feb 17 '26 | Sale | 36.59 | 4,243 | 155,251 | 85,496 | Feb 18 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Jan 08 '26 | Sale | 49.90 | 6,106 | 304,689 | 91,674 | Jan 12 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Dec 16 '25 | Sale | 43.30 | 278 | 12,037 | 97,780 | Dec 17 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Dec 03 '25 | Sale | 39.90 | 6,106 | 243,629 | 98,282 | Dec 05 |
| LIPPS RANDALL A | CHAIRMAN, PRESIDENT AND CEO | Dec 01 '25 | Option Exercise | 27.70 | 28,250 | 782,525 | 414,898 | Dec 03 |
| LIPPS RANDALL A | CHAIRMAN, PRESIDENT AND CEO | Dec 01 '25 | Sale | 35.97 | 28,250 | 1,016,093 | 386,648 | Dec 03 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Nov 17 '25 | Sale | 34.90 | 3,473 | 121,208 | 104,388 | Nov 18 |
| Manley Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Sep 12 '25 | Sale | 33.25 | 3,880 | 129,010 | 110,653 | Sep 16 |
| LIPPS RANDALL A | CHAIRMAN, PRESIDENT AND CEO | Mar 14 '25 | Buy | 33.13 | 10,561 | 349,874 | 333,610 | Mar 18 |
| PARRISH MARK W | Director | Dec 10 '24 | Sale | 47.30 | 12,000 | 567,638 | 58,427 | Dec 12 |